Short answer
Pulmonx Corp (LUNG) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $22M (up 5.5% year over year) with net income of −$14M.
Q3 2025 key financials · XBRL
- Revenue
- $22M
- +5.5% YoY · −9.9% QoQ
- Net income
- −$14M
- +1.3% YoY · +8.0% QoQ
- Operating margin
- -66.9%
- Gross margin
- 74.7%
- EPS (diluted)
- −$0.34
- +5.6% YoY · +10.5% QoQ
Source: XBRL data from the Pulmonx Corp (LUNG) Q3 2025 10-Q on SEC EDGAR. USD.
Pulmonx Corp Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: no newly added or explicitly changed risk factors disclosed this quarter versus 10-K
- Most material update: net losses $43.6M vs $43.2M prior year YTD, accumulated deficit $511.1M, emphasizing ongoing losses and need for revenue growth
- Regulatory risk: extensive approval requirements in US and abroad for Zephyr Valve and potential new products, delays or failures affect commercialization
- Operational risk: dependence on hospital access negotiations and physician training capacity to drive adoption impacting near-term sales growth
- Financial risk: reliance on additional capital financing with potential difficulty obtaining funds on acceptable terms may force operational cutbacks
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Pulmonx Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.